Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816996 | 1.00 | MEN1 (0.46) | MEN1MAPTKMT2ASLC5A2SLC5A1 | |
| SCHEMBL499287 | 0.86 | SLC5A2 (0.38) | MEN1MAPTKMT2ASLC5A2SLC5A1 | |
| SCHEMBL12782162 | 0.85 | CCR5 (0.47) | MEN1MAPTKMT2ACCR5HTR2A | |
| SCHEMBL500031 | 0.84 | SLC6A4 (0.37) | MEN1MAPTKMT2ASLC5A2SLC5A1 | |
| SCHEMBL500175 | 0.83 | CA2 (0.38) | MAPTSLC5A2SLC5A1KDM4EALDH1A1 | |
| SCHEMBL3381486 | 0.83 | ALOX15 (0.39) | MEN1MAPTKMT2ASLC5A2SLC5A1 | |
| SCHEMBL1457579 | 0.82 | APP (0.40) | MEN1MAPTKMT2ASLC5A2SLC5A1 | |
| SCHEMBL37715 | 0.82 | SLC5A2 (0.47) | MAPTSLC5A2SLC5A1CCR5KDM4E | |
| SCHEMBL1539254 | 0.82 | SLC5A2 (0.47) | MAPTSLC5A2SLC5A1CCR5ALDH1A1 | |
| SCHEMBL10540001 | 0.81 | MEN1 (0.58) | MEN1MAPTKMT2ASLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462670-A | Method for preparing enggliflozin by one-pot method | 福安药业集团重庆博圣制药有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED (IN) | 2019-07-04 | — | — | US | claimed |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED | 2017-08-31 | — | — | US | claimed |
| EP-2360165-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | claimed |
| EP-2295422-A2 | Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production | Boehringer Ingelheim International GmbH (DE) | 2011-03-16 | — | — | EP | claimed |
| CN-116462670-A | Method for preparing enggliflozin by one-pot method | 福安药业集团重庆博圣制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116462670-A | Method for preparing enggliflozin by one-pot method | 福安药业集团重庆博圣制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023080243-A1 | METHOD FOR PRODUCING C-ARYLGLUCOSIDE DERIVATIVE | 株式会社トクヤマ | 2023-05-11 | — | — | WO | disclosed |
| CN-108285439-B | Carbonoside sodium glucose transport protein body 2 inhibitor | 江苏天士力帝益药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023005587-A1 | SYNTHESIS METHOD FOR EMPAGLIFLOZIN KEY INTERMEDIATE | 山东铂源药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20060142210-A1 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006064033-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006002912-A1 | D-XYLOPYRANOSYL-SUBSTITUTED PHENYLS, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF, AND METHODS FOR PRODUCING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | US | disclosed |
| WO-2005092877-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202814-A1 | PROCESSES FOR PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | MEN1 3121/4885MAPT 1111/4885KMT2A 2864/4885 |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GPR119 | MEN1 2572/4885MAPT 977/4885KMT2A 3337/4885 |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | SLC5A1, SLC5A2, SLC2A1 | MEN1 2381/4885MAPT 1274/4885KMT2A 3844/4885 |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | MEN1 3100/4885MAPT 1216/4885KMT2A 2810/4885 |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | MEN1 3825/4885MAPT 1457/4885KMT2A 1445/4885 |
| US-20060142210-A1 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, SLC5A1, SLC5A2 | MEN1 2784/4885MAPT 427/4885KMT2A 3947/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | MEN1 3459/4885MAPT 340/4885KMT2A 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.